Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Phase 3
Completed
- Conditions
- Infections, Nosocomial
- Registration Number
- NCT00150332
- Lead Sponsor
- Pfizer
- Brief Summary
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- infection due to methicillin-resistant Staphylococcus aureus
Read More
Exclusion Criteria
- hypersensitivity to linezolid
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Resolution of infection at the time of completion of therapy
- Secondary Outcome Measures
Name Time Method Adverse events
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇯🇵Okayama, Japan